India Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The India Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $49.1 Million in 2025 and projected to reach to $102.6 Million by 2030, representing a compound annual growth rate of 15.9%. India's HPV test and Pap smear market is poised for substantial growth over the next five years, driven by increasing government initiatives for cervical cancer prevention and rising healthcare awareness among women.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- This represents a compound annual growth rate (CAGR) of 15.9%, significantly outpacing global market expansion.
- India's accelerating adoption of cervical cancer screening programs, coupled with rising awareness of HPV-related health risks and increasing healthcare infrastructure investment, is driving this expansion across urban and emerging markets. The market growth in India is fueled by government initiatives promoting preventive healthcare, growing female workforce participation, and expanding access to diagnostic facilities in tier-2 and tier-3 cities.
- India's healthcare sector modernization and the introduction of cost-effective screening solutions are making HPV testing and Pap smear procedures more accessible to the broader population.
- Between 2025 and 2030, India is expected to witness substantial market penetration as public health campaigns intensify and private diagnostic centers expand their cervical cancer screening offerings..
Key Market Statistics
- CAGR (2025-2030) 15.9% CAGR
- Market Size, 2025 ~USD 49.1 Million
- Forecast, 2030 ~USD 102.6 Million
- Country India
India Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Rapid Market Expansion :
India's HPV test and Pap smear market is growing at 15.9% CAGR, nearly 60% faster than the global average of 10%, driven by increased cervical cancer screening initiatives and government health programs.
Market Size Trajectory :
The Indian market is valued at USD 49.1 million in 2025 and is projected to more than double to USD 102.6 million by 2030, reflecting strong demand for preventive healthcare solutions.
Rising Awareness & Screening Programs :
Government-backed cervical cancer screening programs, coupled with growing awareness among Indian women about HPV-related health risks, are accelerating adoption of diagnostic testing across urban and semi-urban regions.
Healthcare Infrastructure Development :
Expansion of diagnostic centers, improved laboratory capabilities, and increasing accessibility to screening services in tier-2 and tier-3 cities are creating significant growth opportunities for market players in India.
India Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- The market's 15.9% CAGR significantly outpaces global growth, reflecting India's emerging focus on preventive healthcare and early disease detection.
- Expanding diagnostic infrastructure, coupled with declining test costs and improved accessibility, will drive market penetration across diverse demographic segments. Key growth catalysts include the integration of HPV testing into national health programs, rising disposable incomes enabling greater healthcare spending, and growing partnerships between public health authorities and private diagnostic providers.
- As India continues to strengthen its cervical cancer screening framework and enhance laboratory capabilities, the market is expected to attract significant investment from both domestic and international healthcare companies, further accelerating market expansion through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- India's HPV test and Pap smear market is projected to more than double from USD 49.1 million in 2025 to USD 102.6 million by 2030, driven by a 15.9% CAGR.
- Government-backed cervical cancer screening initiatives and rising health awareness in India are accelerating market adoption across both urban and rural populations.
- India's expanding diagnostic infrastructure and cost-effective screening solutions are making HPV testing increasingly accessible in tier-2 and tier-3 cities.
- The market growth in India is supported by increasing female workforce participation and preventive healthcare prioritization within the Indian healthcare ecosystem.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
India Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 64.9 | 69.7 | 76.2 | 84.1 | 94 | 106.3 | 121.2 | 139.8 | 12.9 |
| VAGINAL CANCER SCREENING | 5 | 5.4 | 6.1 | 6.8 | 7.7 | 8.9 | 10.3 | 12 | 14.8 |
| TOTAL | 69.9 | 75.1 | 82.2 | 90.9 | 101.7 | 115.2 | 131.5 | 151.9 | 13.1 |
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need India-specific market data to assess demand for HPV testing equipment, understand regulatory requirements, identify distribution channels, and plan manufacturing or partnership strategies in this high-growth market.
- Healthcare Providers & Diagnostic Centers : Diagnostic labs and healthcare facilities require market insights to evaluate service expansion opportunities, benchmark pricing strategies, understand patient demand patterns, and optimize screening program offerings across Indian regions.
- Pharmaceutical & Biotech Companies : Companies developing HPV vaccines, testing reagents, or related therapeutics need India market intelligence to guide R&D investments, commercialization strategies, and partnerships with local healthcare stakeholders.
- Healthcare Investors & Private Equity : Investment firms evaluating opportunities in India's healthcare sector require detailed market sizing, growth projections, and competitive analysis to make informed investment decisions in diagnostic and screening businesses.
- Government & Policy Organizations : Health ministries and policy bodies need market data to design effective cervical cancer screening programs, allocate healthcare budgets, evaluate public-private partnerships, and measure program impact across Indian states.
Key Companies in the India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise valuation of India's HPV and Pap smear market (USD 49.1M in 2025) with detailed 5-year forecasts to 2030, enabling accurate business planning and investment decisions specific to the Indian market.
- Competitive Landscape Intelligence : Understand India-specific market dynamics, key players, and competitive positioning to identify partnership opportunities, market entry strategies, and differentiation approaches tailored to Indian healthcare regulations and consumer preferences.
- Growth Driver Analysis : Gain insights into India-specific factors driving 15.9% CAGR, including government screening programs, awareness campaigns, infrastructure expansion, and demographic trends to capitalize on emerging opportunities.
- Regional Expansion Strategy : Develop targeted go-to-market strategies for tier-1, tier-2, and tier-3 Indian cities with data on healthcare accessibility, diagnostic center distribution, and regional screening adoption patterns.
- Investment & Stakeholder Alignment : Present compelling market data to investors, board members, and stakeholders demonstrating India's high-growth potential in cervical cancer diagnostics, justifying resource allocation and strategic initiatives.
Frequently asked questions
What is the current market size of HPV testing and Pap smear services in India?
India's HPV test and Pap smear market was valued at USD 49.1 million in 2025 and is expected to reach USD 102.6 million by 2030.
What is the projected growth rate for India's HPV testing market?
India's HPV test and Pap smear market is projected to grow at a compound annual growth rate (CAGR) of 15.9% from 2025 to 2030.
What factors are driving market growth in India?
Key drivers include government cervical cancer screening initiatives, rising health awareness, expanding diagnostic infrastructure, cost-effective screening solutions, and increased female workforce participation in India.
How is India's market performance compared to global trends?
India's HPV test and Pap smear market is growing at 15.9% CAGR, significantly outpacing the global market CAGR of 10%, indicating stronger regional demand and adoption.
Which regions in India are experiencing the highest market growth?
While urban centers lead adoption, India is witnessing accelerated growth in tier-2 and tier-3 cities due to expanding diagnostic facilities and government health initiatives.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
